


Fig. 1



Primary screening: Assay #1-3 (ELISA's).





Fig. 2

Secondary screening Assay #4-7 :



Assay #4: FVIIa/TF amidolytic activity:

competition




Assay #5: FVIIa/TF proteolytic activity (factor X activation):

competition



Assay #6: Binding of FVIIa to TF₁₋₂₀₉ (BlAcore):

3: TF₁₋₂₀₉



Assay #7: Clotting assay:







Fig. 3

Final screening Assay #8-10 :

Assay #8: FVIIa/TF proteolytic activity (factor X activation) on cells (J82)



Assay #9: Binding properties on J82 cells (competition with ^{125}I -FVIIa)



Detection of phosphorylated MAPK by kinase assay (Biotrack)

Fig. 4

5/11




Fig. 5




Fig. 6




Fig. 7

Only anti-TF antibody preventing FVIIa binding inhibits TF/FVIIa-mediated signaling




Fig. 8




Fig. 9




Fig. 10




Fig. 11